


=> d l12
 L12 HAS NO ANSWERS
 L12 STR



VAR G1=C/N
 VAR G2=O/S/N
 VAR G3=7/6/8
 VAR G4=18/17/22
 NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RSPEC 7 4 17
 NUMBER OF NODES IS 24

STEREO ATTRIBUTES: NONE


=> search l12
 ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:sss
 ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:subset
 ENTER SUBSET L# OR (END):l11
 ENTER SUBSET SEARCH SCOPE - SAMPLE, FULL, RANGE, OR (END):ful
 FULL SUBSET SEARCH INITIATED 13:56:03 FILE 'REGISTRY'
 FULL SUBSET SCREEN SEARCH COMPLETED - 88 TO ITERATE

100.0% PROCESSED 88 ITERATIONS 37 ANSWERS
 SEARCH TIME: 00.00.01

L13 37 SEA SUB=L11 SSS FUL L12

=> d scan

L13 37 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 IN Urea, N-[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]-N'-[4-(2-hydroxyphenoxy)phenyl]- (9CI)
 MF C19 H20 N4 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> fil caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	107.90	365.69

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-18.88

FILE 'CAPLUS' ENTERED AT 13:56:15 ON 24 APR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Apr 2003 VOL 138 ISS 17
FILE LAST UPDATED: 23 Apr 2003 (20030423/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l13

L14 4 L13

=> d bib abs 1-4

L14 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2003 ACS

AN 2003:22837 CAPLUS

DN 138:73089

TI Preparation of N-phenyloxyphenylcarboxamides as anticholesteremic agents

IN Schmeck, Carsten; Mueller, Ulrich; Schmidt, Gunter; Pernerstorfer, Josef; Bischoff, Hilmar; Kretschmer, Axel; Voehringer, Verena; Faeste, Christiane; Haning, Helmut; Woltering, Michael

PA Bayer Aktiengesellschaft, Germany

SO PCT Int. Appl., 111 pp.

CODEN: PIXXD2


DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003002519	A1	20030109	WO 2002-EP6638	20020617
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,			

CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 DE 10131462 A1 20030109 DE 2001-10131462 20010629
 PRAI DE 2001-10131462 A 20010629
 OS MARPAT 138:73089
 GI



AB Title compds. [I; X = O, S, SO, SO₂, CH₂, CHF, CF₂, etc.; R₁, R₂ = H, alkyl; R₃, R₄ = H, halo, cyano, alkyl, CF₃, CHF₂, CH₂F, vinyl, cycloalkyl; R₅ = H, alkyl, halo; R₆ = alkyl, Br, Cl, etc.; R₇ = H, alkyl, alkanoyl; Z = NHSO₂R₃₆, NHCO₂R₃₇, NHCONR₃₈R₃₉, NHCOR₄₀; R₃₆-R₄₀ = (substituted) alkyl, alkenyl, cycloalkyl, aryl, heterocyclyl, heteroaryl], were prepd. as anticholesteremic agents (no data). Thus, 4-(4-[tert-butyl(dimethyl)silyloxy]-3-isopropylphenoxy)-3,5-dimethylaniline (prepn. given) in THF was stirred with hexanoyl chloride and dimethylaminopyridine for 16 h at room temp. followed by further addn. of hexanoyl chloride and stirring to give 73% N-[4-(4-hydroxy-3-isopropylphenoxy)-3,5-dimethylphenyl]hexanamide.

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2003 ACS

AN 1999:425745 CAPLUS

DN 131:87909

TI Inhibition of p38 kinase activity using substituted heterocyclic ureas

IN Dumas, Jacques; Khire, Uday; Lowinger, Timothy Bruno; Paulsen, Holger; Riedl, Bernd; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Hatoum-Mokdad, Holia; Johnson, Jeffrey; Lee, Wendy; Redman, Aniko

PA Bayer Corporation, USA

SO PCT Int. Appl., 126 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9932111	A1	19990701	WO 1998-US26080	19981222
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2315720	AA	19990701	CA 1998-2315720	19981222
AU 9919971	A1	19990712	AU 1999-19971	19981222
AU 739642	B2	20011018		
EP 1041982	A1	20001011	EP 1998-964709	19981222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

JP 2001526223 T2 20011218 JP 2000-525102 19981222
 PRAI US 1997-995750 A 19971222
 WO 1998-US26080 W 19981222
 OS MARPAT 131:87909
 GI



AB A method for treatment of p38-mediated disease other than cancer comprises administration of ANHCONHB [I; A = substituted isoxazolyl, pyrazolyl, thienyl, furyl; B = (substituted) mono-, di-, or tricyclic aryl, heteroaryl contg. 5-6 membered arom. structure contg. 0-4 N, O, or S atoms]. Reaction of 4-(4-pyridinylthio)aniline with 3-tert-butyl-5-isoxazolyl isocyanate in toluene gave title compd. II. In an in vitro p38 kinase assay, I displayed IC50 values of 1-10 .mu.M.

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS

AN 1999:425740 CAPLUS

DN 131:73648

TI Inhibition of raf kinase using substituted heterocyclic ureas

IN Dumas, Jacques; Khire, Uday; Lowinger, Timothy Bruno; Paulsen, Holger; Riedl, Bernd; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Hatoum-Mokdad, Holia; Johnson, Jeffrey; Lee, Wendy; Redman, Aniko

PA Bayer Corporation, USA

SO PCT Int. Appl., 163 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9932106	A1	19990701	WO 1998-US26078	19981222
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2315717	AA	19990701	CA 1998-2315717	19981222
	AU 9921989	A1	19990712	AU 1999-21989	19981222
	EP 1047418	A1	20001102	EP 1998-965981	19981222
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2001526220	T2	20011218	JP 2000-525097	19981222
	BR 9814374	A	20020514	BR 1998-14374	19981222
	NO 2000003232	A	20000821	NO 2000-3232	20000621
PRAI	US 1997-996343	A	19971222		
	WO 1998-US26078	W	19981222		
OS	MARPAT 131:73648				
GI					



AB A method for treatment of cancerous cell growth mediated by raf kinase comprises administration of urea derivs. ANHCONHB [I; A = substituted isoxazolyl, thienyl, thiadiazolyl, furyl, pyrazolyl, etc.; B = (substituted) mono-, di-, or tricyclic aryl, heteroaryl contg. 0-4 N, O, or S atoms]. Reaction of 4-phenyloxyphenyl isocyanate with 5-amino-3-tert-butylisoxazole in methylene chloride and heating at reflux temp. for 2 days gave title compd. II. In an in vitro raf kinase assay, I displayed IC₅₀ values of 1-10 μ M.

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2003 ACS

AN 1979:6401 CAPLUS

DN 90:6401

TI Fungicidal 1,3,4-thiadiazol-2-yl ureas

IN Regel, Erik; Frohberger, Paul Ernst; Paul, Volker

PA Bayer A.-G., Fed. Rep. Ger.

SO Ger. Offen., 31 pp.

CODEN: GWXXBX


DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2712630	A1	19780928	DE 1977-2712630	19770323
	US 4174398	A	19791113	US 1978-882833	19780302
	NL 7803046	A	19780926	NL 1978-3046	19780321
	DK 7801325	A	19780924	DK 1978-1325	19780322
	JP 53119875	A2	19781019	JP 1978-31793	19780322
	FR 2384763	A1	19781020	FR 1978-8306	19780322
	BR 7801766	A	19781219	BR 1978-1766	19780322
	DE 2821437	A1	19781130	DE 1978-2821437	19780516
	BE 867173	A1	19780922	BE 1978-187778	19780517
	NL 7805332	A	19781121	NL 1978-5332	19780517
	FR 2390893	A1	19781215	FR 1978-15490	19780517
PRAI	DE 1977-2712630		19770323		
	GB 1977-20706		19770517		

GI



AB Thiadiazolylureas I (R = H, halogen; R₁ = alkyl; R₂ = optionally substituted phenyl) were prepd. and demonstrated fungicidal activity. Thus, 2-methylamino-1,3,4-thiadiazole was treated with 4-ClC₆H₄NCO to give 83.5% I (R = H, R₁ = Me, R₂ = 4-ClC₆H₄) (II). Wheat seed contaminated with 5 g Tilletia caries chlamydospores/kg was treated with 1 kg/kg II and total inhibition of germination of the chlamydospores resulted.

=> d hitstr 4


L14 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2003 ACS

IT 68429-66-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 68429-66-3 CAPLUS

CN Urea, N'-[4-(4-chlorophenoxy)phenyl]-N-methyl-N-1,3,4-thiadiazol-2-yl-
(9CI) (CA INDEX NAME)



=> s 127

L28 3 L27

=> d bib abs hitstr 1-3

L28 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2003 ACS

AN 2002:777922 CAPLUS

DN 137:279193

TI Preparation of imidazolylalkyl-aminopiperidines as HIV inhbitors

IN Edlin, Christopher David; Redshaw, Sally; Smith, Ian Edward David; Walter, Daryl Simon

PA F. Hoffmann-La Roche A.-G., Switz.

SO PCT Int. Appl., 179 pp.



CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002079186	A2	20021010	WO 2002-EP3193	20020321
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003069276	A1	20030410	US 2002-104117	20020322
PRAI	GB 2001-8099	A	20010330		
OS	MARPAT 137:279193				
GI					




AB Title compds. I [R1 = H, alkyl, cycloalkyl, allyl, aryl, heterocyclyl; R2-3 = H, alkyl, cycloalkyl, allyl, aryl, heterocyclyl; X = S, O; A = imidazolyl] were prepd. For instance, N-tert-butoxycarbonyl-4-piperidone was used to alkylate aniline (CH₂Cl₂, HOAc, NaHB(OAc)₃), the product converted to the corresponding carbamoyl chloride (CH₂Cl₂/PhMe, NaHCO₃, Cl₂CO) which was reacted with methylamine to give the urea intermediate. This was deprotected and the resulting piperidine alkylated with 5-methyl-2-(4-trifluoromethylphenyl)-1H-imidazole-4-carboxaldehyde (CH₂Cl₂, NaHB(OAc)₃) to afford II. In the gp120-sCD4-CCR5 binding assay, compds. of the invention had IC₅₀ of about 0.5 to about 1500 nM. Compds. I prevent the human immunodeficiency virus (HIV) from entering cells by blocking interaction of the viral envelope protein gp120 with a chemokine receptor on the cell surface. I are useful for the treatment of diseases mediated by the human immunodeficiency virus (HIV), either alone or in combination with other inhibitors of HIV viral replication or with pharmacoenhancers.

IT **466665-56-5P**, 1-Benzyl-3-(5-methyl-[1,3,4]thiadiazol-2-yl)-1-[1-[[5-methyl-2-(4-trifluoromethylphenyl)-1H-imidazol-4-yl]methyl]piperidin-4-yl]urea
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (HIV inhibitor; prepn. of imidazolylalkyl-aminopiperidines as HIV inhbitors)

RN 466665-56-5 CAPLUS

CN Urea, N'-(5-methyl-1,3,4-thiadiazol-2-yl)-N-[1-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl]methyl]-4-piperidinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



L28 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2003 ACS

AN 1999:425740 CAPLUS

DN 131:73648

TI Inhibition of raf kinase using substituted heterocyclic ureas

IN Dumas, Jacques; Khire, Uday; Lowinger, Timothy Bruno; Paulsen, Holger; Riedl, Bernd; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Hatoum-Mokdad, Holia; Johnson, Jeffrey; Lee, Wendy; Redman, Aniko

PA Bayer Corporation, USA

SO PCT Int. Appl., 163 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9932106	A1	19990701	WO 1998-US26078	19981222
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2315717	AA	19990701	CA 1998-2315717	19981222
AU 9921989	A1	19990712	AU 1999-21989	19981222
EP 1047418	A1	20001102	EP 1998-965981	19981222

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO


JP 2001526220	T2	20011218	JP 2000-525097	19981222
BR 9814374	A	20020514	BR 1998-14374	19981222
NO 2000003232	A	20000821	NO 2000-3232	20000621

PRAI US 1997-996343 A 19971222

WO 1998-US26078 W 19981222

OS MARPAT 131:73648

GI



AB A method for treatment of cancerous cell growth mediated by raf kinase comprises administration of urea derivs. ANHCONHB [I; A = substituted isoxazolyl, thienyl, thiadiazolyl, furyl, pyrazolyl, etc.; B = (substituted) mono-, di-, or tricyclic aryl, heteroaryl contg. 0-4 N, O, or S atoms]. Reaction of 4-phenyloxyphenyl isocyanate with 5-amino-3-tert-butylisoxazole in methylene chloride and heating at reflux temp. for 2 days gave title compd. II. In an in vitro raf kinase assay, I displayed IC50 values of 1-10 μ M.


IT 229002-43-1P 229002-44-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of substituted heterocyclic ureas for treatment of cancerous cell growth mediated by raf kinase)


RN 229002-43-1 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]-N'-[6-(3-pyridinyloxy)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 229002-44-2 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]-N'-[6-[(6-methyl-3-pyridinyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2003 ACS

AN 1995:582595 CAPLUS

DN 123:33047

TI Preparation of 1-(imidazolylalkyl)-3-ureido-1,4-benzodiazepine derivatives
as cholecystokinin (CCK) antagonists

IN Sato, Yoshiya

PA Fujisawa Pharmaceuticals Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 21 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

KIND

DATE _____

APPLICATION NO.

DATE _____

PI JP 07002843

A2

19950106

JP 1994-45559

19940316

PRAI GB 1993-8013


19930419

GB 1993-22270


19931029

OS MARPAT 123:33047


GI



I



II



AB The title compds. (I; R1 = H, halo; R2 = H, imino-protective group; R3 = Ph, heterocyclyl, or phenyl-lower alkyl each optionally substituted by .gtoreq.1 substituents; A = lower alkylene), useful for treating disorders of appetite regulation (e.g. loss of appetite), diseases related to exacerbated function of the smooth muscle of intestinal tract, anxiety, and mental diseases (e.g. schizophrenia), are prepd. Thus, 4-chlorophenyl


isocyanate was added to a soln. of 1,4-benzodiazepine deriv. (II; R = trityl, R1 = H) in THF at room temp. and the resulting mixt. was stirred for 2 h to give, after detritylation by treatment with 6 N aq. HCl/MeOH, a title compd. II.HCl (R = H, R1 = Q) (III). III in vitro inhibited 67.0% the binding of [125I]CCK-8 to a CCK receptor prepn. from homogenized rat cerebral cortex.

IT 163486-65-5P 163486-70-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of (imidazolylalkyl)ureidobenzodiazepinone derivs. as cholecystokinin (CCK) antagonists)

RN 163486-65-5 CAPLUS

CN Urea, N-[5-(2-fluorophenyl)-2,3-dihydro-2-oxo-1-[[1-(triphenylmethyl)-1H-imidazol-4-yl]methyl]-1H-1,4-benzodiazepin-3-yl]-N'-(5-methyl-1,3,4-thiadiazol-2-yl)- (9CI) (CA INDEX NAME)



RN 163486-70-2 CAPLUS

CN Urea, N-[5-(2-fluorophenyl)-2,3-dihydro-1-(1H-imidazol-4-ylmethyl)-2-oxo-1H-1,4-benzodiazepin-3-yl]-N'-(5-methyl-1,3,4-thiadiazol-2-yl)-, hydrochloride (9CI) (CA INDEX NAME)

